RxDoctor Payments Data

Frank Bacque, MD

Urology · Lafayette, LANPI 1093794299

Payments from drug & device makers

$381in general payments, 2019–2025

Across 9 payments — averaging $42.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procept Biorobotics Corporation$125
  • Dornier Medtech America, Inc$87
  • Boston Scientific$60
  • Astellas Pharma US Inc$39
  • Axonics, Inc.$34
  • AbbVie$24
  • plus $11 from 1 others

What the payments were for

  • Food & beverage$381100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Procept Biorobotics Corporation1$125
Dornier Medtech America, Inc1$87
Boston Scientific2$60
Astellas Pharma US Inc1$39
Axonics, Inc.2$34
AbbVie1$24
Urogen Pharma, Inc.1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$381 in reported general payments places this provider in the 15th percentile of 199 urology providers in Louisiana.

See all urology providers in Louisiana

Medicare billing

Part B allowed, 2024
$116,072
Medicare patients
336
Services billed
2,680

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron37$18,318
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst269$11,167
Tamsulosin Hcl717$10,192
Finasteride523$9,889
Methenamine Hippurate71$4,553
Mirabegron ErMirabegron13$4,282
Silodosin31$3,060
Dutasteride85$2,427
Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl24$2,018
Doxycycline Monohydrate72$1,932
Alfuzosin Hcl ErAlfuzosin Hcl19$521
Allopurinol79$497
Ciprofloxacin Hcl71$481
Fluconazole18$389
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip18$350

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$39$18,31837 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 199 urology providers in Louisiana.

Other urology in Lafayette

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →